Dr. Mukherjee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Elm and Carlton Streets
Scott Bieler Clinical Science Center, 9th Floor P-934
Buffalo, NY 14263Phone+1 716-845-1300Fax+1 716-845-8935- Is this information wrong?
Education & Training
University of OklahomaMS, Clinical and Translational Science, 2016 - 2018- University of OklahomaFellowship, Hematology-Oncology, Chief Fellow, James N. George award for the outstanding fellow in hematology-oncology, 2015 - 2018
Saint Joseph HospitalResidency, Internal Medicine, 2012 - 2015- Nilratan Sircar Medical CollegeM.B.B.S, Medicine , 2004 - 2010
NRS Medical College CalcuttaClass of 2010
Certifications & Licensure
NY State Medical License 2018 - 2025
OK State Medical License 2015 - 2019
IL State Medical License 2012 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Gold Humanism Honor Society GHHS, 2018
- Member, Occult Primary Panel National Comprehensive Cancer Network, 2018
- Board of Directors Esophageal Cancer Action Network, 2018
- Join now to see all
Clinical Trials
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Start of enrollment: 2015 May 13
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Start of enrollment: 2019 Jul 22
Roles: Contact, Sub-Investigator
- Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2023 Mar 07
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Exploring Demographic Differences and Outcomes in Early-Onset Colorectal Cancer.Siromoni, B., Groman, A., Parmar, K., Mukherjee, S., Vadehra, D.> ;JCO Oncology Practice. 2024 Feb 23
- Association between Environmental Temperature and Survival in Gastroesophageal Cancers: A Population Based Study.George, A., Attwood, K., Roy, A., Siromoni, B., Repasky, E., Gupta, K., Gupta, A., Gandhi, S., Singh, A., Mukherjee, S.> ;Cancers. 2023 Dec 22
- 1 citationsMetabolic Dysregulation Explains the Diverse Impacts of Obesity in Males and Females with Gastrointestinal Cancers.Spencer R Rosario, Bowen Dong, Yali Zhang, Hua-Hsin Hsiao, Emily Isenhart, Jianmin Wang, Erin M Siegel, Arta M Monjazeb, Dwight H Owen, Prasenjit Dey, Fred K Tabung, D...> ;International Journal of Molecular Sciences. 2023 Jun 29
- Join now to see all
Journal Articles
- Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies.Huang H, Salavaggione O, Rivera L, Mukherjee S, Brekken R, Tennant B, Iyer R, Adjei A., Arch Biochem Biophys, 11/12/2018
Abstracts/Posters
- Can DNA Methylation Patterns be used as Predictive Biomarkers for Chemotherapy Response in Osteosarcoma?Mukherjee S, Jeffries M, Rivas A, Malik R, Ibrahimi S, Fung K, White J, Meyer W, Vesely S, Barkauskas D, Hall D, Cherry M., J Clin Oncol 36, 2018 (suppl; abstr 11525), 6/1/2018
- Efficacy of PD-1/PD-L1 Therapy: do proton pump inhibitors affect the outcome?Mukherjee S, Khalid B, Ibrahimi S, Morton J, Roman D, Zhao D, Aljumaily R., J Clin Oncol 36, 2018 (suppl 5S; abstr 208), 1/2018
- Effect of Body Mass Index and Albumin level on Outcomes of Patients Receiving Anti PD-1/PD-L1 TherapyIbrahimi S, Mukherjee S, Roman D, King C, Machiorlatti M, Aljumaily R., J Clin Oncol 36, 2018 (suppl 5S; abstr 213), 1/2018
- Join now to see all
Lectures
- Phase II study of trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- On the Shoulders of Giants: Historical Approaches to Immunotherapy in Solid TumorsASCO annual meeting, Chicago, IL - 6/2017
- NANETS Regional NET Education: Multidisciplinary Management of NET CancersNorth American Neuroendocrine Tumor Society Regional meeting, Oklahoma City, OK - 11/2017
Authored Content
- Conducting Research During Your Oncology Fellowship: Obstacles and Opportunities6/28/2016
- Burnout Among Oncology Fellows: A Personal Perspective2/23/2016
Press Mentions
FTD/TPI plus Oxaliplatin Well-Tolerated but Not Broadly Effective as Treatment for Esophageal CancerApril 18th, 2023- Combo carboplatin/paclitaxel Dubbed New Standard of Care for Anal CancerJune 26th, 2020
- Expanding Immunotherapy Options for Patients with Advanced Breast and Colorectal CancerApril 12th, 2022
- Join now to see all
Professional Memberships
- American Society of Clinical OncologyMember
- American Association for Cancer ResearchMember
- American College of GastroenterologyMember
- American Society of HematologyMember
- Member
Other Languages
- Bengali, Hindi
Hospital Affiliations
Roswell Park Comprehensive Cancer CenterBuffalo, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
